ArticleMethods in molecular biology (Clifton, N.J.)2027
Genetic and Epigenetic Manipulation Using CRISPR Techniques in Ewing Sarcoma.
Article in Methods in molecular biology (Clifton, N.J.), 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRISPR-based technologies have transformed experimental biology by enabling precise, efficient, and programmable manipulation of the genome and epigenome. This chapter provides a comprehensive and practical guide to genetic and epigenetic editing using CRISPR technology, with a particular focus on applications in Ewing sarcoma cell models. We describe strategies for CRISPR-mediated gene knockout (CRISPR KO) via nonhomologous end joining (NHEJ), precise gene knock-in (CRISPR KI) through homology-directed repair (HDR), and reversible transcriptional modulation using CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa). We emphasize the use of ribonucleoprotein (RNP) delivery of Cas9 and single guide RNAs, which offers improved editing efficiency, reduced off-target activity, and enhanced safety compared to plasmid-based approaches. Detailed protocols are provided for guide RNA design, RNP assembly, electroporation-based delivery, single-cell cloning, and molecular validation of edited clones. In addition, we outline best practices for HDR template design, discuss strategies to improve KI efficiency, and address common challenges such as polyploidy, variable editing rates, and DNA-mediated cytotoxicity. For CRISPRi and CRISPRa applications, we describe plasmid-based systems employing catalytically inactive Cas9 fused to transcriptional repressors or activators, enabling potentially tunable and reversible control of endogenous gene expression. Throughout the chapter, practical advice, troubleshooting tips, and critical considerations are included to facilitate successful implementation across diverse experimental settings. Collectively, this chapter serves as a detailed methodological resource for researchers aiming to employ CRISPR-based engineering for functional studies.
Indexed as
Identifiers
42879020What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.